|
1
|
Hu DG, Rogers A and Mackenzie PI:
Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression
in liver cancer cells via the p53 pathway. Mol Pharmacol.
85:887–897. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khasraw M, Bell R and Dang C: Epirubicin:
Is it like doxorubicin in breast cancer? A clinical review. Breast.
21:142–149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miyoshi Y, Kurosumi M, Kurebayashi J,
Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ,
Okishiro M, et al: Topoisomerase IIalpha-positive and
BRCA1-negative phenotype: Association with favorable response to
epirubicin-based regimens for human breast cancers. Cancer Lett.
264:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okishiro M, Kim SJ, Tsunashima R, Nakayama
T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y and Noguchi S: MDM2
SNP309 and TP53 R72P associated with severe and febrile neutropenia
in breast cancer patients treated with
5-FU/epirubicin/cyclophosphamide. Breast Cancer Res Treat.
132:947–953. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aogi K, Saeki T, Nakamura S, Kashiwaba M,
Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, et al: A
multicenter, phase II study of epirubicin/cyclophosphamide followed
by docetaxel and concurrent trastuzumab as primary systemic therapy
for HER-2 positive advanced breast cancer (the HER2NAT study). Int
J Clin Oncol. 18:598–606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nasr M, Nafee N, Saad H and Kazem A:
Improved antitumor activity and reduced cardiotoxicity of
epirubicin using hepatocyte-targeted nanoparticles combined with
tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm
Biopharm. 88:216–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Appel JM, Zerahn B, Moller S, Christensen
HM, Søgaard P, Ejlertsen B, Fogh-Andersen N, Jensen BV and Nielsen
DL: Long-term heart function after adjuvant epirubicin chemotherapy
for breast cancer. Acta Oncol. 51:1054–1061. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng
F, Zhou J, Liu L, Zhang CX, Zhao WY and Lu WL: Liposomes, modified
with PTD (HIV-1) peptide, containing epirubicin and celecoxib, to
target vasculogenic mimicry channels in invasive breast cancer.
Biomaterials. 35:7610–7621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haisma HJ, Boven E, van Muijen M, de Jong
J, van der Vijgh WJ and Pinedo HM: A monoclonal
antibody-beta-glucuronidase conjugate as activator of the prodrug
epirubicin-glucuronide for specific treatment of cancer. Br J
Cancer. 66:474–478. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu J, Sheng Y, Xu F, Yu Y and Chen Y:
Quantitative subcellular study of transferrin receptor-targeted
doxorubicin and its metabolite in human breast cancer cells. Eur J
Drug Metab Pharmacokinet. 39:301–310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tortorella S and Karagiannis TC:
Transferrin receptor-mediated endocytosis: A useful target for
cancer therapy. J Membr Biol. 247:291–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oh S, Kim BJ, Singh NP, Lai H and Sasaki
T: Synthesis and anti-cancer activity of covalent conjugates of
artemisinin and a transferrin-receptor targeting peptide. Cancer
Lett. 274:33–39. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han L, Huang R, Liu S, Huang S and Jiang
C: Peptide-conjugated PAMAM for targeted doxorubicin delivery to
transferrin receptor overexpressed tumors. Mol Pharm. 7:2156–2165.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malarvizhi GL, Retnakumari AP, Nair S and
Koyakutty M: Transferrin targeted core-shell nanomedicine for
combinatorial delivery of doxorubicin and sorafenib against
hepatocellular carcinoma. Nanomedicine. 10:1649–1659.
2014.PubMed/NCBI
|
|
15
|
Nam JP, Park SC, Kim TH, Jang JY, Choi C,
Jang MK and Nah JW: Encapsulation of paclitaxel into lauric
acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic
drug delivery and site-specific targeted delivery. Int J Pharm.
457:124–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee JH, Engler JA, Collawn JF and Moore
BA: Receptor mediated uptake of peptides that bind the human
transferrin receptor. Eur J Biochem. 268:2004–2012. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kato J, Kobune M, Ohkubo S, Fujikawa K,
Tanaka M, Takimoto R, Takada K, Takahari D, Kawano Y, Kohgo Y and
Niitsu Y: Iron/IRP-1-dependent regulation of mRNA expression for
transferrin receptor, DMT1 and ferritin during human erythroid
differentiation. Exp Hematol. 35:879–887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qian G, Wang Z, Zhao J, Li D, Gao W, Wang
B, Sui D, Qu X and Chen Y: Synthesis and anti-cancer cell activity
of pseudo-ginsenoside Rh2. Steroids. 92:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dixit S, Novak T, Miller K, Zhu Y, Kenney
ME and Broome AM: Transferrin receptor-targeted theranostic gold
nanoparticles for photosensitizer delivery in brain tumors.
Nanoscale. 7:1782–1790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu J, Sheng Y, Xu F, Yu Y and Chen Y:
Quantitative subcellular study of transferrin receptor-targeted
doxorubicin and its metabolite in human breast cancer cells. Eur J
Drug Metab Pharmacokinet. 39:301–310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wirth GJ, Schandelmaier K, Smith V, Burger
AM and Fiebig HH: Microarrays of 41 human tumor cell lines for the
characterization of new molecular targets: Expression patterns of
cathepsin B and the transferrin receptor. Oncology. 71:86–94. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lo YL, Ho CT and Tsai FL: Inhibit
multidrug resistance and induce apoptosis by using glycocholic acid
and epirubicin. Eur J Pharm Sci. 35:52–67. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pakunlu RI, Wang Y, Saad M, Khandare JJ,
Starovoytov V and Minko T: In vitro and in vivo intracellular
liposomal delivery of antisense oligonucleotides and anticancer
drug. J Control Release. 114:153–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin Y, Jiang D, Li Y, Han X, Yu D, Park JH
and Jin YH: Effect of sun ginseng potentiation on epirubicin and
paclitaxel-induced apoptosis in human cervical cancer cells. J
Ginseng Res. 39:22–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Richardson DR and Ponka P: The molecular
mechanisms of the metabolism and transport of iron in normal and
neoplastic cells. Biochim Biophys Acta. 1331:1–40. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yashunsky V, Shimron S, Lirtsman V, Weiss
AM, Melamed-Book N, Golosovsky M, Davidov D and Aroeti B: Real-time
monitoring of transferrin-induced endocytic vesicle formation by
mid-infrared surface plasmon resonance. Biophys J. 97:1003–1012.
2009. View Article : Google Scholar : PubMed/NCBI
|
